About ARDX

Ardelyx is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of innovative, minimally-systemic, small molecule therapeutics that work exclusively in the gastrointestinal tract to treat gastrointestinal and cardio-renal diseases. Ardelyx has developed a proprietary drug discovery and design platform enabling it, in a rapid and cost-efficient manner, to discover and design novel drug candidates. Utilizing this platform, Ardelyx has discovered and designed tenapanor, which it is evaluating for the treatment of constipation-predominant irritable bowel syndrome, or IBS-C, and management of hyperphosphatemia in patients with end stage renal disease. In addition to tenapanor, Ardelyx is developing RDX022, a non-absorbed polymer for the treatment of hyperkalemia, or high potassium, in kidney and heart disease patients. Ardelyx is also advancing several research programs focused in gastrointestinal and cardio-renal diseases. Ardelyx is located in Fremont, California.
Primary Exchange: NASDAQ
SIC Pharmaceutical Preparations
NAICS Pharmaceutical Preparation Manufacturing

ARDX is a Holding In These ETFs:

ETF Ticker ETF Name Net Assets Net Assets Raw # Holdings # Holdings Raw Weight Weight Raw Market Value Market Value Raw
URTY ProShares UltraPro Russell2000 105.8 M 1.05784E+08 2,016 2016 0.0% 1.90251E-05 6 K 6321
UWM ProShares Ultra Russell2000 184.1 M 1.84148E+08 2,016 2016 0.0% 2.54602E-05 10 K 10299
PXSV Invesco Russell 2000 Pure Value ETF 78.2 M 7.82E+07 321 321 0.04% 0.00039 30 K 30475
ITOT iShares Core S&P Total U.S. Stock Market ETF 18.7 B 1.87292E+10 3,568 3568 0.0% 0 38 K 37840
IWC iShares Microcap ETF 916.2 M 9.16246E+08 1,452 1452 0.04% 0.0004 348 K 347666
IWM iShares Russell 2000 ETF 44.9 B 4.48577E+10 2,006 2006 0.01% 0.0001 3.2 M 3162100
IWN iShares Russell 2000 Value ETF 9.2 B 9.22952E+09 1,371 1371 0.01% 0.0001 1.3 M 1332460
IWV iShares Russell 3000 ETF 9.7 B 9.71954E+09 2,931 2931 0.0% 0 29 K 28506

Wait, Before You Leave...